Table 3 Baseline characteristics of treatment groups
| Â | Placebo | Group A | Group B | Group C |
|---|---|---|---|---|
N completed (started) | 23 (29) | 20 (25) | 22 (24) | 26 (29) |
Age (years) | 51.3 ± 1.0 | 50.5 ± 1.7 | 52.3 ± 1.8 | 52.1 ± 1.6 |
Gender (F: M %) | 72:28 | 76:24 | 75:25 | 52:48 |
ARA Functional Class II/III, % | 69 : 31 | 76 : 24 | 67 : 33 | 69 : 31 |
Kellgren Lawrence Criteria Grade 2/3, % | 76 : 24 | 83 : 17 | 83 : 17 | 82 : 18 |
WOMAC A | 8.7 ± 1.0 | 9.1 ± 1.2 | 8.0 ± 1.1 | 8.7 ± 1.0 |
WOMAC B | 3.4 ± 0.5 | 3.5 ± 0.5 | 3.3 ± 0.4 | 3.3 ± 0.4 |
WOMAC C | 36.4 ± 3.9 | 38.4 ± 4.0 | 34.7 ± 4.2 | 32.8 ± 4.3 |
WOMAC Total | 48.6 ± 5.2 | 51.1 ± 6.4 | 46.4 ± 5.6 | 44.8 ± 5.5 |
VAS | 72.9 ± 2.0 | 72.9 ± 3.0 | 70.1 ± 2.5 | 70.7 ± 2.4 |